Receive your personalized plan and get your medication delivered
While the share of ESI enrollees with a GLP-1 drug claim has been increasing, still only a relatively modest number of people have a claim Since 2012, the share of non-elderly adults with ESI that have a GLP-1 drug claim has grown more than eightfold (717.7% increase)
Why did my patient receive less than the prescribed amount of their medication
The FDA also required changes to the labels to achieve a more uniform presentation of side effects and risk information for all of the drugs in the GLP-1 category, including adding or changing subsections for Acute Pancreatitis and Severe Gastrointestinal Adverse Reactions and revising the Patient Counseling section and Medication Guide. Some of the labels were also updated with post-marketing reports of hair loss (alopecia) and the neurological symptom of altered sense of touch, or dysethesia
Most injection site reactions fall into the expected and manageable category
For any compound to work transdermally, it must be small enough to penetrate through multiple skin layers and achieve therapeutic concentrations in the bloodstream